Lichen planus and lichenoid dermatoses : Conventional and emerging therapeutic strategies - 15/10/18
Abstract |
Having reviewed the diverse clinical subtypes of lichenoid disease and the postulated molecular basis thereof in the first article in this 2-part continuing medical education series, we discuss herein the existing and emerging treatment strategies in the most common clinical forms of lichenoid inflammation and provide an overview of their pharmacodynamics and evidence base. The scope of this review is not to exhaustively discuss treatment modalities for all lichenoid variants discussed in the previous article of this series. Instead, the focus will be on frequently encountered subtypes of lichen planus and on linking mechanisms of disease with mechanisms of drug action. Future directions and potential avenues for translational research will also be discussed.
Le texte complet de cet article est disponible en PDF.Keywords : emerging drugs for lichenoid inflammation, lichen planus therapeutics, lichenoid variant therapeutics
Abbreviations used : LP, LPP, NB-UVB, NLP, PUVA, RCT, TCI, TCS
Plan
Dr Tziotzios, Dr Brier, and Mr Lee contributed equally to this article. |
|
Funding sources: None. |
|
Conflicts of interest: None disclosed. |
|
Date of release: November 2018 |
|
Expiration date: November 2021 |
Vol 79 - N° 5
P. 807-818 - novembre 2018 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?